Treatment for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Barbara Ann Karmanos Cancer Institute, Detroit, MI
Multiple Myeloma+6 More
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a booster dose of the Moderna COVID-19 vaccine can increase antibody levels in people with hematologic malignancies.

See full description

Eligible Conditions

  • Multiple Myeloma
  • AL Amyloidosis
  • Chronic Lymphocytic Leukemia (CLL)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Daily phone calls or video chats for 1 week following vaccine administration, and then weekly after that until 4 weeks after vaccination..

Day 28
Observed response rate of anti-SARS-CoV2 antibody seroconversion.
Week 4
Observed AEs and SAEs
Day 28
Observed rate of STRONG POSITIVE anti-SARS-CoV2 antibody response

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

0 Treatment Group

This trial requires 171 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: measured 28 days (+/- 3 days) following a booster dose of the moderna covid-19 vaccine.
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly measured 28 days (+/- 3 days) following a booster dose of the moderna covid-19 vaccine. for reporting.

Who is running the study

Principal Investigator
J. Z.
Jeffrey Zonder, Principal Investigator
Barbara Ann Karmanos Cancer Institute

Closest Location

Barbara Ann Karmanos Cancer Institute - Detroit, MI

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18 years of age or older
Previously diagnosed with MM/AL amyloidosis (Cohorts 1 or 3) or other hematologic malignancy (Cohorts 2 or 3).
Previously received any one of the available COVID-19 vaccines (between 4 and 36 weeks prior to enrollment)
Anti-SARS-CoV2 IgG antibody titer of results less than 1.0 units (Cohorts 1 and 2), or 1.0-1.99 units (Cohort 3). Antibody titers will be measured within 14 days of enrollment.
If currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is ENCOURAGED BUT NOT REQUIRED (physician discretion).-

Patient Q&A Section

What causes hematologic neoplasms?

"Most cases are caused by unknown factors. If you think you have a problem with your blood or bone marrow, ask your doctor if you have any unusual symptoms or findings. A complete medical history is important to diagnose a blood disorder before testing, and other tests such as a CBC (complete blood count) or bone marrow biopsy can help determine what type of blood disorder you might have. It is very important to detect kidney problems early to prevent further complications." - Anonymous Online Contributor

Unverified Answer

What is the latest research for hematologic neoplasms?

"Hematologic neoplasms continue to be challenging diseases for researchers to understand as we move forward into the 21st century. Overall, there were no exciting new treatments approved during our review period. However, there was a significant amount of progress in the development of targeted therapies based on abnormal proteins present in tumors. For instance, small molecule tyrosine kinase inhibitors such as imatinib (Gleevec) and dasatinib (Sprycel) have been shown to significantly improve progression-free survival in people with chronic myeloid leukemia." - Anonymous Online Contributor

Unverified Answer

Is treatment typically used in combination with any other treatments?

"In our study, only 20% of patients received two or more different treatments, but the use of a single agent did not affect the overall survival and progression-free survival rates." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing hematologic neoplasms?

"The risk of developing any type of hematologic neoplasm was 2% at age 40, 1% at age 70, 0.5% at 80 years and 0.2% at 90 years. The time interval between exposure and first diagnosis was 18 months, 10 years, 11 years, 8 years, 6 years, 5 years and 3 years, respectively. Because of the low number of cases, all types were combined together In a recent study." - Anonymous Online Contributor

Unverified Answer

What is treatment?

"Why people with hematological malignancies choose supportive care rather than active treatment has not been studied. Allowing patients to make medical decisions about their care is both respectful and ethical. This article presents a framework for explaining why people might take this approach." - Anonymous Online Contributor

Unverified Answer

What is hematologic neoplasms?

"Hematologic neoplasms are any cancer that starts in the blood or bone marrow. They are rare and have a very poor prognosis. It includes leukemias, lymphomas, Hodgkin’s disease, non-Hodgkin’s disease, acute myelogenous leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, and multiple myelomas. There are more than 100 different types of hematologic cancers. The most common type of leukemia seen in adults is chronic myelogenous leukemia. It accounts for about 40% of all cases of leukemia. Leukemia is treated with chemotherapy, radiation therapy, immunotherapy, stem cell transplant, or gene therapy." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in treatment for therapeutic use?

"The development of new treatments has been slower than expected over the past few years. Many treatments have been approved only recently, meaning they were not available before 2013. Therapeutic agents with potentially greater effectiveness and fewer side effects will help alleviate the pain and suffering faced by many cancer patients. As we move forward, we can expect to see rapid advances in the field of cancer research and treatment." - Anonymous Online Contributor

Unverified Answer

How does treatment work?

"Currently, there is no effective therapy for [Hairy cell leukaemia] (HCL). It is important to understand what causes HCL to grow and invade healthy marrow. There are many hypotheses, but they are mostly speculative. It is important to remember that there is no cure for [Hairy cell leukaemia] (HCL). There is hope that future treatments will help people live longer and maybe even stop [Hairy cell leukaemia] (HCL). Along with looking at the genetics of the disease, researchers are looking into different treatments. The [Kappa inhibitor|kappa]] pathway is being researched for its effectiveness against HCLs because it is known to prevent the growth of normal blood cells." - Anonymous Online Contributor

Unverified Answer

What are the signs of hematologic neoplasms?

"Hematological neoplasms most often present with symptoms of mass effect of the tumor such as abdominal pain, backaches, and abdominal fullness. Other nonspecific complaints include fever, red blood cell count (anemia), and thrombocytopenia. The diagnosis of hematological malignancy requires confirmation by additional diagnostic tests including blood smear microscopy, bone marrow aspiration, and biopsy, and family history." - Anonymous Online Contributor

Unverified Answer

What are common treatments for hematologic neoplasms?

"Patients with hematologic malignancies commonly receive multiple chemotherapy regimens that are tailored based upon their specific genotype or phenotype. These therapies include (1) high-dose anthracycline plus cytarabine based regimens; (2) single agent anthracyclines; (3) multiple chemotherapeutic regimens that contain etoposide; (4) allogeneic stem cell transplantation; (5) autologous stem cell transplantation; (6) immunoablative chemotherapy regimens; (7) targeted agents; and (8) combination therapies." - Anonymous Online Contributor

Unverified Answer

What does treatment usually treat?

"At present, no guidelines exist for the management of acute leukemia and solid tumors. Despite the fact that many patients are admitted to hospital, routine clinical practice is still lacking." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Multiple Myeloma by sharing your contact details with the study coordinator.